Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways.

Bar-Yehuda S, Stemmer SM, Madi L, Castel D, Ochaion A, Cohen S, Barer F, Zabutti A, Perez-Liz G, Del Valle L, Fishman P.

Int J Oncol. 2008 Aug;33(2):287-95.

PMID:
18636149
2.

Adenosine modulates cell growth in the human breast cancer cells via adenosine receptors.

Panjehpour M, Karami-Tehrani F.

Oncol Res. 2007;16(12):575-85.

PMID:
18351132
3.

Inhibition of cell proliferation through cell cycle arrest and apoptosis by thio-Cl-IB-MECA, a novel A3 adenosine receptor agonist, in human lung cancer cells.

Kim SJ, Min HY, Chung HJ, Park EJ, Hong JY, Kang YJ, Shin DH, Jeong LS, Lee SK.

Cancer Lett. 2008 Jun 18;264(2):309-15. doi: 10.1016/j.canlet.2008.01.037. Epub 2008 Mar 5.

PMID:
18321638
4.

Sensing danger--Hsp72 and HMGB1 as candidate signals.

Williams JH, Ireland HE.

J Leukoc Biol. 2008 Mar;83(3):489-92. Epub 2007 Dec 21. Review.

PMID:
18156188
5.

The ectonucleotidase cd39/ENTPDase1 modulates purinergic-mediated microglial migration.

Färber K, Markworth S, Pannasch U, Nolte C, Prinz V, Kronenberg G, Gertz K, Endres M, Bechmann I, Enjyoji K, Robson SC, Kettenmann H.

Glia. 2008 Feb;56(3):331-41.

PMID:
18098126
6.

Cl-IB-MECA inhibits human thyroid cancer cell proliferation independently of A3 adenosine receptor activation.

Morello S, Petrella A, Festa M, Popolo A, Monaco M, Vuttariello E, Chiappetta G, Parente L, Pinto A.

Cancer Biol Ther. 2008 Feb;7(2):278-84. Epub 2007 Nov 14.

PMID:
18059189
7.

The A3 adenosine receptor: an enigmatic player in cell biology.

Gessi S, Merighi S, Varani K, Leung E, Mac Lennan S, Borea PA.

Pharmacol Ther. 2008 Jan;117(1):123-40. Epub 2007 Sep 22. Review.

PMID:
18029023
8.

The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis.

Bar-Yehuda S, Silverman MH, Kerns WD, Ochaion A, Cohen S, Fishman P.

Expert Opin Investig Drugs. 2007 Oct;16(10):1601-13. Review.

PMID:
17922624
9.

A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells.

Zarek PE, Huang CT, Lutz ER, Kowalski J, Horton MR, Linden J, Drake CG, Powell JD.

Blood. 2008 Jan 1;111(1):251-9. Epub 2007 Oct 1.

10.

Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling.

Raskovalova T, Lokshin A, Huang X, Su Y, Mandic M, Zarour HM, Jackson EK, Gorelik E.

Cancer Res. 2007 Jun 15;67(12):5949-56.

11.

Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.

Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC.

J Exp Med. 2007 Jun 11;204(6):1257-65. Epub 2007 May 14.

12.

MAP kinase signalling pathways in cancer.

Dhillon AS, Hagan S, Rath O, Kolch W.

Oncogene. 2007 May 14;26(22):3279-90. Review.

PMID:
17496922
13.

G protein regulation of MAPK networks.

Goldsmith ZG, Dhanasekaran DN.

Oncogene. 2007 May 14;26(22):3122-42. Review.

PMID:
17496911
14.

Differential regulation and properties of MAPKs.

Raman M, Chen W, Cobb MH.

Oncogene. 2007 May 14;26(22):3100-12. Review.

PMID:
17496909
15.

Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells.

Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Simioni C, Leung E, Maclennan S, Baraldi PG, Borea PA.

Mol Pharmacol. 2007 Aug;72(2):395-406. Epub 2007 May 8.

16.

Hypoxia-dependent anti-inflammatory pathways in protection of cancerous tissues.

Lukashev D, Ohta A, Sitkovsky M.

Cancer Metastasis Rev. 2007 Jun;26(2):273-9. Review.

PMID:
17404693
17.

Adenosine A(3) receptor agonist acts as a homeostatic regulator of bone marrow hematopoiesis.

Hofer M, Pospísil M, Znojil V, Holá J, Vacek A, Streitová D.

Biomed Pharmacother. 2007 Jul;61(6):356-9. Epub 2007 Mar 8.

PMID:
17383145
18.

Activation of adenosine 2A receptors attenuates allograft rejection and alloantigen recognition.

Sevigny CP, Li L, Awad AS, Huang L, McDuffie M, Linden J, Lobo PI, Okusa MD.

J Immunol. 2007 Apr 1;178(7):4240-9.

19.

Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A(3) adenosine subtype.

Gessi S, Merighi S, Varani K, Cattabriga E, Benini A, Mirandola P, Leung E, Mac Lennan S, Feo C, Baraldi S, Borea PA.

J Cell Physiol. 2007 Jun;211(3):826-36.

PMID:
17348028
20.

Supplemental Content

Support Center